Timothy E. Morey

Corporate Officer/Principal en University of Florida .

Health Technology

Consumer Services

Perfil

Dr. Timothy E.
Morey, MD, is a Professor at University of Florida and a Principal at Kegonsa Capital Partners LLC.
He is on the Board of Directors at Nanomedex Pharmaceuticals, Inc. He received his doctorate degree from the University of Florida.

Cargos activos de Timothy E. Morey

Empresas	Cargo	Inicio
University of Florida	Corporate Officer/Principal	25/11/2009

Todos los cargos activos de Timothy E. Morey

Antiguos cargos conocidos de Timothy E. Morey.

Empresas	Cargo	Fin
NanoMedex Pharmaceuticals, Inc. NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI.	Fundador	-

Ver el detalle de la experiencia de Timothy E. Morey.

Formación de Timothy E. Morey.

University of Florida

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Timothy E. Morey.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
NanoMedex Pharmaceuticals, Inc. NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI.	Health Technology